We are a bioanalytical lab that has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.
Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics & Pharmacodynamics (PK/PD)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
Co-Hosted with Bioanalysis Zone
With the question “should we qualify or validate an exploratory biomarker assay before sample testing?” in mind, BioAgilytix’s Dr. Afshin Safavi reviews and discusses the latest scientific and regulatory considerations for the analytical validation of assays for fluid-based biomarkers used in the qualification of drug development tools (DDTs).
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
January 14, 2020Webinar Sneak Peek: What the New AAPS White Paper Recommends for Immunogenicity Assays Supporting Biosimilars
January 2, 2020Bioanalytical Strategies to Support Biosimilar Programs: How BioAgilytix is Helping to Shape Best Practices
December 12, 2019BioAgilytix Welcomes Dominic Marasco to Leadership Team as Chief Commercial Officer
November 4, 2019BioAgilytix Announces Acquisition of Boston-Based Clinical Research Organization Cambridge Biomedical
December 6, 2019CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway
December 2, 2019Immunogenicity Assessment of Gene Therapy Compounds
Services
Platforms
